GELS (54) PCSA (39) SCNX (28) LGVN (27) ⌘ Pro Terminal →

Addex Therapeutics Ltd (ADXN) — RQD Stock Rating Cockpit

$3.09 +5.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.11

Addex Therapeutics Ltd (ADXN) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $5.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADXN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADXN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Addex Therapeutics Ltd (NASDAQ: ADXN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $3.09 (+5.46% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADXN ranks #295 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADXN compare to GELS and PCSA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADXN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GELS (Gelteq Limited) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, ADXN leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADXN?

▼

For Addex Therapeutics Ltd (ADXN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #295 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.11 (+0.79%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADXN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY ADXN SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($147.4K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.01+1.3% Next Q

Q2 (-2Q)

Grade D$3.05-2% Next Q

Q3 (-1Q)

Grade D$2.99+3.3% Next Q

Current

Grade D$3.09-5.6% Hist 90D α

Trajectory: D (40) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ADXN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ADXN currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.27) and Max Pain ($3.24) forces dealer call-delta covering toward $10.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADXN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ADXN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE7% OF RANGE

L: $3$3.09H: $10

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ADXN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

14/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like ADXN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADXN)

✓Walkthrough of ADXN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADXN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.41%▼ DESCENDING CHANNEL

2026-11-03O $2.93H $3.09L $2.93C $3.09VOL 2.6K

RES: $5.06SUP: $1.34SMA50: $3.27SMA200: $5.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADXN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADXN Butterfly Map → + Track ADXN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADXN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADXN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADXN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADXN)

Health Care Rank #295 of 1016 ⚔️ GELS vs ADXN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADXN vs. GELS, PCSA, SCNX, LGVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Addex Therapeutics Ltd (ADXN) ranks #295 by composite RQD confidence (48/100, grade D) and #938 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, ADXN leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ADXN at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADXN ACTIVE Addex Therapeutics Ltd	D	48/100	—	—	—	+5.46%	$5.3M	Benchmark Subject
GELS Gelteq Limited	D+	54/100	—	—	—	-3.14%	$5.2M	/gels-vs-adxn →
PCSA Processa Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	0.00%	$5.3M	/pcsa-vs-adxn →
SCNX Scienture Holdings Inc.	E	28/100	—	76.8%	-35.0%	-7.74%	$5.3M	/scnx-vs-adxn →
LGVN Longeveron Inc. (Class A)	E	27/100	—	67.0%	-35.0%	-4.57%	$5.3M	/lgvn-vs-adxn →

2. ADXN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Addex Therapeutics Ltd (ADXN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ADXN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADXN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ADXN compare to GELS and PCSA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ADXN?

Where is ADXN trading relative to its 50-day, 200-day, and 52-week technical levels?

ADXN last traded at $3.09 (+5.46% on volume of 2,626 shares), positioning the stock -5.50% below its 50-day simple moving average ($3.27) and -46.26% below its 200-day simple moving average ($5.75). Across its 52-week range of $2.56 to $10.43, ADXN sits at the 6.7% percentile with a 14-day RSI of 49.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.70 to $3.48).

ADXN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ADXN stock right now?

Addex Therapeutics Ltd (ADXN) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is ADXN's 12-month price target and RQD AI Jury consensus?

ADXN's 12-month base price target is $2.95 (range $2.3 to $10.95), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ADXN RQD Cockpit ADXN 12M Forecast ADXN Earnings & Move ADXN Dividends & DRIP ADXN Insiders & 13F ADXN Whale Options ADXN Profit Sankey ADXN News & Why

ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ADXN — Addex Therapeutics Ltd: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:20:31Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ADXN scores 46 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Pillar breakdown:

Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%, meaning the rating attributes no current return on capital and no free-cash-flow generation to the equity.
Whale 13F Flow: 3 / 20. This pillar, which covers institutional accumulation and options positioning, is the weakest score in the set, indicating little supportive institutional flow in the rating's inputs.
Insider Conviction: 9 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow; the score is below midpoint.
Macro Regime Fit: 9 / 20. The rating cites Beta of 1.0 and sector sensitivity; the score is below midpoint.
Forensic Balance Sheet: 13 / 20. The rating cites Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar, though it still sits below the midpoint of its 20-point scale.

For a prospective investor evaluating the stock today, the rating's pillars point to limited cash-generation evidence and weak institutional support, partially offset by a comparatively steadier balance-sheet reading. Upside drivers would need to come from factors outside the rated fundamentals, since the rating itself does not show earnings, cash generation, or meaningful institutional accumulation. The absence of valuation multiples (P/E, EV/EBITDA) means the valuation tradeoff cannot be assessed from these sources. Market data show a price of 2.93 against a 52-week range of $2.56 - $10.43, with a market cap of $5.0M and trading volume of 2366; these are facts for context, not a valuation conclusion.

Business

Addex Therapeutics Ltd (ADXN) is listed on NASDAQ in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. Not available in source data for products sold, customers served, or revenue model.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, five items are tagged to ADXN, each classified as "MARKET WIRE" with a YELLOW light:

Yahoo! Finance Canada and Stocktwits items are generic market-coverage summaries referencing market action, institutional positioning, and fundamental catalysts, without specific event detail.
Stock Titan reports that outstanding shares remain unchanged as ADXN issues new shares to its wholly owned subsidiary.
GlobeNewswire reports that ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES.
Benzinga includes ADXN among 12 Health Care stocks moving in a pre-market session.

Risk watch items: the share-issuance and treasury-share items are the only company-specific corporate actions in the feed; their financial effect is not quantified in the sources. Proprietary signals: none are listed in the Butterfly graph.

Open Questions

What are the company's reported revenue, operating income, net income, cash, and debt figures across recent periods?
What products or pipeline assets generate or are expected to generate revenue, and who are its customers or partners?
What is the financial effect of the disclosed share issuance to a wholly owned subsidiary and the creation of treasury shares?
What valuation multiples (P/E, EV/EBITDA, EPS) apply, given that all are unavailable in the source data?
What is the institutional and insider holding and transaction history for ADXN?

ADXN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Addex Therapeutics Ltd (ADXN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADXN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

Addex Therapeutics Ltd (ADXN) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Addex Therapeutics Ltd (ADXN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 22h ago

ADXN: Addex Therapeutics Ltd - ADR Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Addex Therapeutics Ltd (ADXN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Outstanding shares remain unchanged as Addex (ADXN) issues new shares to its wholly owned subsidiary.

Stock Titan report covering Addex Therapeutics Ltd (ADXN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

GlobeNewswire report covering Addex Therapeutics Ltd (ADXN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga report covering Addex Therapeutics Ltd (ADXN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 5d ago

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel sm

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18d ago

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences (NASDAQ:SNTI) stock

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 18d ago

Get insights into the top gainers and losers of Thursday's pre-market session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADXN Bull vs. Bear Conversation Board — What's Your Call at $3.09?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADXN 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.16 (+7.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ADXN (D • RQD 46/100) a Buy at $2.93?

Welcome to the ADXN (Addex Therapeutics Ltd) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.20 (-24.9%)

Spot @ $2.93

Pump the brakes on ADXN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ADXN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Addex Therapeutics Ltd expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.60 (+22.9%)

Spot @ $2.93

ADXN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ADXN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.93 (52-wk range $2.56 - $10.43), any beat on forward guidance forces shorts and underweight funds to chase.